Výsledky vyhledávání - "Agita Jeruma"

Original Versus Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Patients: Real Life Data From Latvia

Autor: Baiba Rozentale, Raimonds Simanis, Agita Jeruma, Seda Arutjunana, Velga Kuse, Ieva Tolmane

Publikováno v: The Open Infectious Diseases Journal. 10:63-70

Background: Despite effective treatment available from 2016 in Latvia, there are restrictions - only patients with fibrosis (F, Metavir) stage 3 to 4 have access to reimbursed medicines. Some patients obtain generic drugs from India. Objective: The a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6922ba1df1e49c08689548bb3d184e4
https://doi.org/10.2174/1874279301810010063

Zobrazit plný text záznamu

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Autor: Wolfgang Vogel, M. Blachier, Lelia Thornton, Wim Laleman, Ieva Tolmane, Antonio Craxì, Mojca Matičič, Hans Van Vlierberghe, Christoph Sarrazin, Laura Harcouet, Joël Mossong, Ilias Gountas, Matthew E. Cramp, Devin Razavi-Shearer, Soo Aleman, Lyudmila Mateva, Ann-Sofi Duberg, Vratislav Nemecek, Jordan Genov, Michael Manns, Anne Øvrehus, Irena Hrstić, Kimberly Murphy, Stefano Vella, Krzysztof Tomasiewicz, Francesco Negro, Nina Weis, Antonio Javier Blasco, Agita Jeruma, Karolin Falconer, Danute Speiciene, Jonas Valantinas, Jose Luis Calleja, Jan Sperl, Gabor Horvath, Filipe Calinas, Peter Jarcuska, Jerneja Videčnik-Zorman, Ivan Schréter, Kathryn Razavi-Shearer, Christophe Moreno, Sergeja Gregorčič, Angelos Hatzakis, Pierre Van Damme, Riina Salupere, Massimo Colombo, Robert J. de Knegt, Peter J Smit, Dijana Nonkovic, Daniela K van Santen, Waldemar Halota, Rui Sarmento-Castro, Jean-Michel Delile, Suzanne Norris, Vana Sypsa, Robert Flisiak, Carole Seguin-Devaux, Martin Lagging, Liana Gheorghe, Mihály Makara, Javier García-Samaniego, Christophe Hézode, Jennifer Kieran, Marian Oltman, Peter Stärkel, Victor de Ledinghen, Pablo Lázaro, Stefan Zeuzem, E. A. Croes, Patrick Hoffmann, Matti Maimets, Francesco Saverio Mennini, Kostas Athanasakis, Chris Estes, Stephen D. Ryder, Sarah Robbins, Françoise Roudot-Thoraval, Martin Kåberg, Kaarlo Simojoki, Sona Frankova, Adrian Goldis, Marietta Simonova, Kyriakos Souliotis, Ken Pasini, Homie Razavi, Rui Tato Marinho, Sarah Blach, Pavol Kristian, Rumiana Mitova, Loreta A. Kondili, Maria Buti, Helen Nde, Boris Lukšić, Henrik Krarup, Dominique Vandijck, Henk W. Reesink, David A. M. C. van de Vijver, Iskren Kotzev, Jessie Gunter, Adriaan J. van der Meer, Martti Färkkilä, Baiba Rozentale, Perttu Arkkila, Krasimir Antonov, Jan Gerstoft, Béla Hunyady, Peer Brehm Christensen, Ivane Gamkrelidze, Valentina Liakina, Michael Gschwantler, Deian Jelev, Tatjana Reic, George V. Papatheodoridis, Jonathan Schmelzer, Daniel Struck

Publikováno v: Krarup, H & European Union HCV Collaborators 2017, ' Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030 : a modelling study ', The Lancet Gastroenterology & Hepatology, vol. 2, no. 5, pp. 325-336 . https://doi.org/10.1016/S2468-1253(17)30045-6
Lancet Gastroenterology & Hepatology, 2(5), 325-336. Elsevier Ltd.
The Lancet Gastroenterology & Hepatology, Vol. 2, No 5 (2017) pp. 325-336
Lancet gastroenterology & hepatology
The lancet. Gastroenterology & hepatology, 2(5), 325-336. HANLEY & BELFUS-ELSEVIER INC
Øvrehus, A L H & European Union HCV Collaborators 2017, ' Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030 : a modelling study ', The Lancet Gastroenterology & Hepatology, vol. 2, no. 5, pp. 325-336 . https://doi.org/10.1016/S2468-1253(17)30045-6

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% red

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6167fe45cfcadfaa8e9dc89df3a54984
https://doi.org/10.1016/s2468-1253(17)30045-6

Zobrazit plný text záznamu

Direct-acting antivirals ombitasvir/paritaprevir/rotonavir+dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia

Autor: Katazyna Polubenko, Arvydas Ambrozaitis, Edita Kazenaite, Daiva Radzisauskiene, Evelina Mockiene, Jolita Jakutiene, Ieva Tolmane, Ligita Jancoriene, Agita Jeruma, Arida Buivydiene

Publikováno v: Hepatitis monthly / Tehran Hepatitis Center, Amsterdam : Kowsar publishing, 2018, vol. 18, no 1, art. no e62105, [p. 1-10]

Background: The current international multicentre open-label, uncontrolled, real-world retrospective study aimed at evaluating the effectiveness and safety of ombitasvir / paritaprevir / ritonavir + dasabuvir ± ribavirin (3D therapy) in treatment-na

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24bd451d493005ca6ed8ef17117013c
https://repository.vu.lt/VU:ELABAPDB26435413&prefLang=en_US

Zobrazit plný text záznamu

Biochemical and Immunogenetic Diagnostic Markers Less Commonly Used for Predicting the Efficacy of Chronic Hepatitis C Etiotropic Therapy

Autor: Eglite J, Ludmila Viksna, Agita Jeruma, Sondore, Socnevs A

Publikováno v: Virology & Mycology.

Introduction: 1,7% of the population of Latvia in 2008 was HCV RNA positive, thus approximately 38 thousands required the CHC antiviral therapy. The objective of the study was to evaluate some biochemical and immunogenetic parameters allowing predict

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50f5f5815eb158c583aa6d5b87f18c4c
https://doi.org/10.4172/2161-0517.1000129

Zobrazit plný text záznamu

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Autor: Altaf Alam, K. Saeed, N. Nugrahini, Fadi H. Mourad, Andri Sanityoso Sulaiman, Abdul Rahman Bizri, Jon G. Jonasson, Liana Gheorghe, S. Alawadhi, Ala I. Sharara, Sarah Blach, Rino Alvani Gani, Do Young Kim, M. Alzaabi, Young Seok Kim, Matti Maimets, S. Priohutomo, A. Löve, Saeed Hamid, Abdullah M. Assiri, H. Al Quraishi, Adel Alqutub, G. Tayyab, Junko Tanaka, H. Qureshi, A. Salamat, P. Aldins, M. S. Choi, M. T. Barakat, Reza Malekzadeh, M. Sadik, Kwang Hyub Han, Young-Suk Lim, J. Videčnik-Zorman, A. Abdou, Jacques E Mokhbat, Zaigham Abbas, Khalid Alswat, G. Sigmundsdottir, B. Karlsdottir, Marwa Sultan, K. Al Jaberi, Devin Razavi-Shearer, A. Al Rifai, Chris Estes, Abdullah S. Alghamdi, A. Sanityoso Sulaiman, Béla Hunyady, F. Al Braiki, B. Sigurdardottir, Ieva Tolmane, Kathryn Razavi-Shearer, S. El Khoury, Gabor Horvath, Y. Al Serkal, M. Taha, Hamad I. Al-Ashgar, Cesar Yaghi, Abdulrahman Aljumah, Danute Speiciene, Riina Salupere, Irsan Hasan, S. Fakhry, Homie Razavi, Evy Yunihastuti, F. Al Hosani, M. A. Al Mulla, Faisal M. Sanai, Mohamed A. Babatin, N. Andrea, L. Al-Dabal, S. Gregorcic, Arif Nawaz, R. Al-Hakeem, E. S. El Hassan, R. Husni, M. Siddiq, David H. Muljono, Adrian Goldis, A. Almessabi, Jonathan Schmelzer, Mojca Maticic, Laurentius A. Lesmana, A. Baqir, Ibrahim Altraif, Faisal Abaalkhail, Shahin Merat, Mihály Makara, A. Abourached, Jonas Valantinas, Asad Chaudhry, T. Diab, M. Ud Din, Muhammad S. Memon, Jessie Gunter, R. A. Sayegh, Seyed Moayed Alavian, A. M. Siddiqui, H. Fridjonsdottir, Bader Faiyaz Zuberi, M. Umar, Magnus Gottfredsson, Baiba Rozentale, Agita Jeruma, Samsuridjal Djauzi, Almoutaz Hashim, A. Ghafoor Khan, Ottar M. Bergmann, Z. Koutoubi, M. A. Yusuf, H. Tarifi, A. Sibley, Faleh Z. Al-Faleh, Wasim Jafri, P. Rassam, J. I. Farooqi, S. Olafsson, Behzad Hajarizadeh, Valentina Liakina, M. Al Khatry

Publikováno v: Journal of viral hepatitis
Razavi, H, Waked, I, Sarrazin, C, Myers, R P, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, M C, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, A J, Brandão Mello, C E, Bruggmann, P, Buti, M, Calleja, J L, Cheinquer, H, Christensen, P B, Clausen, M, Coelho, H S M, Cramp, M E, Dore, G J, Doss, W, Duberg, A S, El-Sayed, M H, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, M L G, Ferreira, P R, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, J A, Gonçales, F L, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, S J, Hofer, H, Husa, P, Kåberg, M, Kaita, K D E, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, R T, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, A L H, Parkes, J, Pasini, K, Peltekian, K M, Ramji, A, Reis, N, Roberts, S K, Rosenberg, W M, Roudot-Thoraval, F, Ryder, S D, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, G E, Sievert, W, Sperl, J, Stärkel, P, Stauber, R E, Thompson, A J, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B & Estes, C 2014, ' The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm ', Journal of Viral Hepatitis, vol. 21, no. Suppl 1, pp. 34-59 . https://doi.org/10.1111/jvh.12248
Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
Razavi, H, Waked, I, Sarrazin, C, Myers, R P, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, M C, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, A J, Brandão Mello, C E, Bruggmann, P, Buti, M, Calleja, J L, Cheinquer, H, Christensen, P B, Clausen, M, Coelho, H S M, Cramp, M E, Dore, G J, Doss, W, Duberg, A S, El-Sayed, M H, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, M L G, Ferreira, P R, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, J A, Gonçales, F L, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, S J, Hofer, H, Husa, P, Kåberg, M, Kaita, K D E, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, R T, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Holm, A L, Parkes, J, Pasini, K, Peltekian, K M, Ramji, A, Reis, N, Roberts, S K, Rosenberg, W M, Roudot-Thoraval, F, Ryder, S D, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, G E, Sievert, W, Sperl, J, Stärkel, P, Stauber, R E, Thompson, A J, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B & Estes, C 2014, ' The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm ', Journal of Viral Hepatitis, vol. 21, no. Suppl 1, pp. 34–59 . https://doi.org/10.1111/jvh.12248
Journal of Viral Hepatitis, Vol. 21 Suppl 1 (2014) pp. 34-59

Gilead Sciences The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ebbc6a8b2a97eb03fc96aa66e20346a
https://hdl.handle.net/10067/1171300151162165141

Zobrazit plný text záznamu

Baltic Post-marketing Study of Pegilated Interferon α-2a 40 KD Efficacy and Safety in Patients with HBeAg–Positive and HBeAg– Negative Chronic Hepatitis B

Autor: Ludmila Viksna, Valentina Sondore, Gunta Sture, Andrejs Ivanovs, Jazeps Keiss, Baiba Rozentale, Agita Jeruma

Publikováno v: Virology & Mycology.

Introduction: Pegilated interferon alpha-2a 40KD (Pegasys?) is registered in European Union, and is indicated for the treatment of HBeAg positive or HBeAg negative chronic hepatitis B in adult patients with compensated liver disease, evidence of vira

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f06e1e1d051fbed134f21a609c96bbe6
https://doi.org/10.4172/2161-0517.1000108

Zobrazit plný text záznamu

Akademický článek

Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study

Autor: Ligita Jančorienė, Baiba Rozentāle, Ieva Tolmane, Agita Jēruma, Riina Salupere, Arida Buivydienė, Jonas Valantinas, Limas Kupčinskas, Jolanta Šumskienė, Eglė Čiupkevičienė, Arvydas Ambrozaitis, Olga Golubovska, Larysa Moroz, Robert Flisiak, Borys Bondar

Publikováno v: Medicina, Vol 59, Iss 9, p 1577 (2023)

Background and objectives: Since 2013, highly effective direct-acting antiviral (DAA) treatment for chronic hepatitis C (CHC) has become available, with cure rates exceeding 95%. For the choice of optimal CHC treatment, an assessment of the hepatitis

Externí odkaz: https://doaj.org/article/2ea1e693a55e415592eb97627adef832

Zobrazit plný text záznamu

Noninvasive Alternatives to Liver Biopsy

Autor: Valentina Sondore, Jazeps Keiss, Ilze Strumfa, Baiba Rozentale, Agita Jeruma, Peteris Prieditis, Ludmila Viksna, Arturs Sochnevs

Publikováno v: Liver Biopsy

During the past 60 years the role and importance of liver biopsy have changed. In 1950s the introduction of liver puncture biopsy was absolute innovation, e.g. in Latvia, and had an invaluable significance. The possibility to compare and/or oppose al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::384da1bf697ecd208c955d432f543345
http://www.intechopen.com/articles/show/title/noninvasive-alternatives-to-liver-biopsy

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání